{"success":true,"data":{"pressRelease":{"id":"31356","rtpr_id":"nGNX64l24P","ticker":"HUMA","exchange":"NASDAQ","all_tickers":["HUMA"],"title":"Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer","author":"Globe Newswire","published_at":"2026-05-12T12:00:02.268Z","article_body":"- Distinguished vascular surgeon brings decades of clinical experience,\ninnovation, and leadership to new role at cutting-edge biotech manufacturer -\n\n- Appointment brings important surgical experience and perspective to\nHumacyte’s corporate leadership team as clinical adoption of Symvess® ramps\nup and pipeline indications move toward planned approval -\n\nDURHAM, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA),\na commercial-stage biotechnology platform company developing universally\nimplantable, bioengineered human tissues at commercial scale, today announced\nthat Todd E. Rasmussen, M.D., has joined the company as Chief Surgical\nOfficer.\n\nIn this role, Dr. Rasmussen will focus on providing peer-to-peer scientific\nsupport, medical education, and technical insights to surgeons and other\nhealthcare providers. He will bring an experienced surgical perspective and\nleadership to the development of education and clinical support materials\naligned with regulatory guidance to optimize the safe, appropriate, and\neffective implantation of Humacyte products.\n\n“The most meaningful advances in surgery occur when clinicians, scientists,\nand engineers work together to translate new innovations to the operating room\nand to the patient’s bedside. I’ve had the privilege of working alongside\nthe team at Humacyte for more than a decade as they created and made available\na pioneering, off-the-shelf biologic conduit. I look forward to building on\nthat shared experience and my own as a surgeon to support U.S. and\ninternational colleagues in the safe and effective integration of this and\nsimilar technologies into clinical practice,” said Dr. Rasmussen.\n\nDr. Rasmussen joins Humacyte with extensive expertise as a vascular surgeon,\nhaving completed a 28-year career in the U.S. Air Force during which he\ndeployed multiple times during the Iraq and Afghanistan Wars and led major\nmedical research programs for the Department of Defense. Following his\nretirement from military service, he joined Mayo Clinic as Professor of\nSurgery and Consultant in Vascular and Endovascular Surgery. Dr. Rasmussen\nwill continue his clinical, educational, and administrative responsibilities\nat Mayo Clinic while serving separately as Chief Surgical Officer at Humacyte.\n\n“Todd Rasmussen is one of the trailblazers of modern vascular surgery, and\nhaving his experience and global reach as part of our team during this pivotal\ntime for the company will be invaluable,” said Laura Niklason, M.D., Ph.D.,\nChief Executive Officer of Humacyte. “Symvess represents a major step\nforward in our ability to expand durable vascular access options for patients,\nand bringing on someone who has consistently driven that progress throughout\nhis career will be instrumental in guiding strategy and real-world\nimplementation going forward.”\n\nUpon retiring from military service at the rank of Colonel in 2021, Dr.\nRasmussen was awarded the Defense Superior Service Medal, the Department of\nDefense’s second-highest non-combat award. He has served as president of the\nAmerican College of Surgeons Excelsior Surgical Society, has authored more\nthan 350 peer-reviewed publications, edited textbooks in vascular trauma and\nvascular surgery, and his work has been cited more than 25,000 times. Dr.\nRasmussen’s innovation and translational research continue to influence the\nfield of surgery and trauma care worldwide.\n\nMayo Clinic has a financial interest in Humacyte. Mayo Clinic will use any\nrevenue it receives to support its not-for-profit mission in patient care,\neducation and research.\n\nAbout Humacyte\n\nHumacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology\nplatform to deliver universally implantable bioengineered human tissues,\nadvanced tissue constructs, and organ systems designed to improve the lives of\npatients and transform the practice of medicine. The Company develops and\nmanufactures acellular tissues to treat a wide range of diseases, injuries,\nand chronic conditions. Humacyte’s Biologics License Application for the\nacellular tissue engineered vessel (ATEV) in the vascular trauma indication\nwas approved by the FDA in December 2024. ATEVs are also currently in\nlate-stage clinical trials targeting other vascular applications, including\narteriovenous (AV) access for hemodialysis and peripheral artery disease\n(PAD). Preclinical development is also underway in coronary artery bypass\ngrafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple\nnovel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in\nhemodialysis was the first product candidate to receive the FDA’s\nRegenerative Medicine Advanced Therapy (RMAT) designation and has also\nreceived FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial\nrepair following extremity vascular trauma and for advanced PAD also have\nreceived RMAT designations. The ATEV received priority designation for the\ntreatment of vascular trauma by the U.S. Secretary of Defense. For more\ninformation, visit www.Humacyte.com.\n\nFor uses other than the FDA approval in the extremity vascular trauma\nindication, the ATEV is an investigational product and has not been approved\nfor sale by the FDA or any other regulatory agency.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements that are based on\nbeliefs and assumptions and on information currently available. In some cases,\nyou can identify forward-looking statements by the following words: “may,”\n“will,” “could,” “would,” “should,” “expect,”\n“intend,” “plan,” “anticipate,” “believe,” “estimate,”\n“predict,” “project,” “potential,” “continue,” “ongoing”\nor the negative of these terms or other comparable terminology, although not\nall forward-looking statements contain these words. These statements involve\nrisks, uncertainties, and other factors that may cause actual results, levels\nof activity, performance, or achievements to be materially different from the\ninformation expressed or implied by these forward-looking statements. Although\nwe believe that we have a reasonable basis for each forward-looking statement\ncontained in this press release, we caution you that these statements are\nbased on a combination of facts and factors currently known by us and our\nprojections of the future, about which we cannot be certain. Forward-looking\nstatements in this press release include, but are not limited to, our plans\nand ability to commercialize Symvess and, if approved by regulatory\nauthorities, our product candidates, successfully and on our anticipated\ntimelines; the degree of market acceptance of and the availability of\nthird-party coverage and reimbursement for Symvess and, if approved by\nregulatory authorities, our product candidates; our ability to manufacture\nSymvess and, if approved by regulatory authorities, our product candidates in\nsufficient quantities to satisfy our clinical trial and commercial needs; the\nanticipated benefits of our ATEVs relative to existing alternatives; our plans\nand ability to execute product development, process development and\npreclinical development efforts successfully and on our anticipated timelines;\nour ability to design, initiate and successfully complete clinical trials and\nother studies for our product candidates and our plans and expectations\nregarding our ongoing or planned clinical trials; the anticipated\ncharacteristics and performance of our ATEVs; the implementation of our\nbusiness model and strategic plans for our business; our ability to execute\nand achieve the expected benefits of our cost-saving measures and whether our\nefforts will result in further actions or additional asset impairment charges\nthat adversely affect our business; and the timing or likelihood of regulatory\nfilings, acceptances and approvals. We cannot assure you that the\nforward-looking statements in this press release will prove to be accurate.\nThese forward-looking statements are subject to a number of significant risks\nand uncertainties that could cause actual results to differ materially from\nexpected results, including, among others, changes in applicable laws or\nregulations, the possibility that Humacyte may be adversely affected by other\neconomic, business, competitive and/or reputational factors, and other risks\nand uncertainties, including those described under the header “Risk\nFactors” in our Annual Report on Form 10-K for the year ended December 31,\n2025 filed by Humacyte with the SEC, and in future SEC filings. Most of these\nfactors are outside of Humacyte’s control and are difficult to predict.\nFurthermore, if the forward-looking statements prove to be inaccurate, the\ninaccuracy may be material. In light of the significant uncertainties in these\nforward-looking statements, you should not regard these statements as a\nrepresentation or warranty by us or any other person that we will achieve our\nobjectives and plans in any specified time frame, or at all. Except as\nrequired by law, we have no current intention of updating any of the\nforward-looking statements in this press release. You should, therefore, not\nrely on these forward-looking statements as representing our views as of any\ndate subsequent to the date of this press release.\n\nHumacyte Investor Contact:\nJoyce Allaire\nLifeSci Advisors LLC\n+1-617-435-6602\njallaire@lifesciadvisors.com\ninvestors@humacyte.com\n\nHumacyte Media Contact:\nRich Luchette\nPrecision Strategies\n+1-202-845-3924\nrich@precisionstrategies.com\nmedia@humacyte.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e81aff26-ead8-404d-aebb-159b45c3e7b1)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX64l24P","title":"Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer","author":"Globe Newswire","ticker":"HUMA","created":"2026-05-12T12:00:02.268Z","tickers":["HUMA"],"exchange":"NASDAQ","article_body":"- Distinguished vascular surgeon brings decades of clinical experience,\ninnovation, and leadership to new role at cutting-edge biotech manufacturer -\n\n- Appointment brings important surgical experience and perspective to\nHumacyte’s corporate leadership team as clinical adoption of Symvess® ramps\nup and pipeline indications move toward planned approval -\n\nDURHAM, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA),\na commercial-stage biotechnology platform company developing universally\nimplantable, bioengineered human tissues at commercial scale, today announced\nthat Todd E. Rasmussen, M.D., has joined the company as Chief Surgical\nOfficer.\n\nIn this role, Dr. Rasmussen will focus on providing peer-to-peer scientific\nsupport, medical education, and technical insights to surgeons and other\nhealthcare providers. He will bring an experienced surgical perspective and\nleadership to the development of education and clinical support materials\naligned with regulatory guidance to optimize the safe, appropriate, and\neffective implantation of Humacyte products.\n\n“The most meaningful advances in surgery occur when clinicians, scientists,\nand engineers work together to translate new innovations to the operating room\nand to the patient’s bedside. I’ve had the privilege of working alongside\nthe team at Humacyte for more than a decade as they created and made available\na pioneering, off-the-shelf biologic conduit. I look forward to building on\nthat shared experience and my own as a surgeon to support U.S. and\ninternational colleagues in the safe and effective integration of this and\nsimilar technologies into clinical practice,” said Dr. Rasmussen.\n\nDr. Rasmussen joins Humacyte with extensive expertise as a vascular surgeon,\nhaving completed a 28-year career in the U.S. Air Force during which he\ndeployed multiple times during the Iraq and Afghanistan Wars and led major\nmedical research programs for the Department of Defense. Following his\nretirement from military service, he joined Mayo Clinic as Professor of\nSurgery and Consultant in Vascular and Endovascular Surgery. Dr. Rasmussen\nwill continue his clinical, educational, and administrative responsibilities\nat Mayo Clinic while serving separately as Chief Surgical Officer at Humacyte.\n\n“Todd Rasmussen is one of the trailblazers of modern vascular surgery, and\nhaving his experience and global reach as part of our team during this pivotal\ntime for the company will be invaluable,” said Laura Niklason, M.D., Ph.D.,\nChief Executive Officer of Humacyte. “Symvess represents a major step\nforward in our ability to expand durable vascular access options for patients,\nand bringing on someone who has consistently driven that progress throughout\nhis career will be instrumental in guiding strategy and real-world\nimplementation going forward.”\n\nUpon retiring from military service at the rank of Colonel in 2021, Dr.\nRasmussen was awarded the Defense Superior Service Medal, the Department of\nDefense’s second-highest non-combat award. He has served as president of the\nAmerican College of Surgeons Excelsior Surgical Society, has authored more\nthan 350 peer-reviewed publications, edited textbooks in vascular trauma and\nvascular surgery, and his work has been cited more than 25,000 times. Dr.\nRasmussen’s innovation and translational research continue to influence the\nfield of surgery and trauma care worldwide.\n\nMayo Clinic has a financial interest in Humacyte. Mayo Clinic will use any\nrevenue it receives to support its not-for-profit mission in patient care,\neducation and research.\n\nAbout Humacyte\n\nHumacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology\nplatform to deliver universally implantable bioengineered human tissues,\nadvanced tissue constructs, and organ systems designed to improve the lives of\npatients and transform the practice of medicine. The Company develops and\nmanufactures acellular tissues to treat a wide range of diseases, injuries,\nand chronic conditions. Humacyte’s Biologics License Application for the\nacellular tissue engineered vessel (ATEV) in the vascular trauma indication\nwas approved by the FDA in December 2024. ATEVs are also currently in\nlate-stage clinical trials targeting other vascular applications, including\narteriovenous (AV) access for hemodialysis and peripheral artery disease\n(PAD). Preclinical development is also underway in coronary artery bypass\ngrafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple\nnovel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in\nhemodialysis was the first product candidate to receive the FDA’s\nRegenerative Medicine Advanced Therapy (RMAT) designation and has also\nreceived FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial\nrepair following extremity vascular trauma and for advanced PAD also have\nreceived RMAT designations. The ATEV received priority designation for the\ntreatment of vascular trauma by the U.S. Secretary of Defense. For more\ninformation, visit www.Humacyte.com.\n\nFor uses other than the FDA approval in the extremity vascular trauma\nindication, the ATEV is an investigational product and has not been approved\nfor sale by the FDA or any other regulatory agency.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements that are based on\nbeliefs and assumptions and on information currently available. In some cases,\nyou can identify forward-looking statements by the following words: “may,”\n“will,” “could,” “would,” “should,” “expect,”\n“intend,” “plan,” “anticipate,” “believe,” “estimate,”\n“predict,” “project,” “potential,” “continue,” “ongoing”\nor the negative of these terms or other comparable terminology, although not\nall forward-looking statements contain these words. These statements involve\nrisks, uncertainties, and other factors that may cause actual results, levels\nof activity, performance, or achievements to be materially different from the\ninformation expressed or implied by these forward-looking statements. Although\nwe believe that we have a reasonable basis for each forward-looking statement\ncontained in this press release, we caution you that these statements are\nbased on a combination of facts and factors currently known by us and our\nprojections of the future, about which we cannot be certain. Forward-looking\nstatements in this press release include, but are not limited to, our plans\nand ability to commercialize Symvess and, if approved by regulatory\nauthorities, our product candidates, successfully and on our anticipated\ntimelines; the degree of market acceptance of and the availability of\nthird-party coverage and reimbursement for Symvess and, if approved by\nregulatory authorities, our product candidates; our ability to manufacture\nSymvess and, if approved by regulatory authorities, our product candidates in\nsufficient quantities to satisfy our clinical trial and commercial needs; the\nanticipated benefits of our ATEVs relative to existing alternatives; our plans\nand ability to execute product development, process development and\npreclinical development efforts successfully and on our anticipated timelines;\nour ability to design, initiate and successfully complete clinical trials and\nother studies for our product candidates and our plans and expectations\nregarding our ongoing or planned clinical trials; the anticipated\ncharacteristics and performance of our ATEVs; the implementation of our\nbusiness model and strategic plans for our business; our ability to execute\nand achieve the expected benefits of our cost-saving measures and whether our\nefforts will result in further actions or additional asset impairment charges\nthat adversely affect our business; and the timing or likelihood of regulatory\nfilings, acceptances and approvals. We cannot assure you that the\nforward-looking statements in this press release will prove to be accurate.\nThese forward-looking statements are subject to a number of significant risks\nand uncertainties that could cause actual results to differ materially from\nexpected results, including, among others, changes in applicable laws or\nregulations, the possibility that Humacyte may be adversely affected by other\neconomic, business, competitive and/or reputational factors, and other risks\nand uncertainties, including those described under the header “Risk\nFactors” in our Annual Report on Form 10-K for the year ended December 31,\n2025 filed by Humacyte with the SEC, and in future SEC filings. Most of these\nfactors are outside of Humacyte’s control and are difficult to predict.\nFurthermore, if the forward-looking statements prove to be inaccurate, the\ninaccuracy may be material. In light of the significant uncertainties in these\nforward-looking statements, you should not regard these statements as a\nrepresentation or warranty by us or any other person that we will achieve our\nobjectives and plans in any specified time frame, or at all. Except as\nrequired by law, we have no current intention of updating any of the\nforward-looking statements in this press release. You should, therefore, not\nrely on these forward-looking statements as representing our views as of any\ndate subsequent to the date of this press release.\n\nHumacyte Investor Contact:\nJoyce Allaire\nLifeSci Advisors LLC\n+1-617-435-6602\njallaire@lifesciadvisors.com\ninvestors@humacyte.com\n\nHumacyte Media Contact:\nRich Luchette\nPrecision Strategies\n+1-202-845-3924\nrich@precisionstrategies.com\nmedia@humacyte.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e81aff26-ead8-404d-aebb-159b45c3e7b1)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-12T12:00:02.644734531Z","server_sent_at_ms":1778587202644},"received_at":"2026-05-12T12:00:02.885Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}